These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 10692355

  • 1. Evolution of drug resistance in experimental populations of Candida albicans.
    Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, Kohn LM.
    J Bacteriol; 2000 Mar; 182(6):1515-22. PubMed ID: 10692355
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.
    Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J.
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2378-86. PubMed ID: 8585712
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of resistance to fluconazole in Candida albicans clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis.
    Salari S, Khosravi AR, Mousavi SA, Nikbakht-Brojeni GH.
    J Mycol Med; 2016 Mar; 26(1):35-41. PubMed ID: 26627124
    [Abstract] [Full Text] [Related]

  • 4. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D, Coste AT.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [Abstract] [Full Text] [Related]

  • 5. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance.
    Walsh TJ, Kasai M, Francesconi A, Landsman D, Chanock SJ.
    J Med Vet Mycol; 1997 Jan; 35(2):133-7. PubMed ID: 9147273
    [Abstract] [Full Text] [Related]

  • 6. Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India.
    Mane A, Vidhate P, Kusro C, Waman V, Saxena V, Kulkarni-Kale U, Risbud A.
    Mycoses; 2016 Feb; 59(2):93-100. PubMed ID: 26648048
    [Abstract] [Full Text] [Related]

  • 7. Molecular aspects of fluconazole resistance development in Candida albicans.
    Franz R, Ruhnke M, Morschhäuser J.
    Mycoses; 1999 Feb; 42(7-8):453-8. PubMed ID: 10546486
    [Abstract] [Full Text] [Related]

  • 8. Expression of Major Efflux Pumps in Fluconazole-Resistant Candida albicans.
    Pourakbari B, Teymuri M, Mahmoudi S, Valian SK, Movahedi Z, Eshaghi H, Mamishi S.
    Infect Disord Drug Targets; 2017 Feb; 17(3):178-184. PubMed ID: 28558643
    [Abstract] [Full Text] [Related]

  • 9. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.
    Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM.
    J Antimicrob Chemother; 2004 Jan; 53(1):74-80. PubMed ID: 14657086
    [Abstract] [Full Text] [Related]

  • 10. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M, López-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF.
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.
    White TC.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1482-7. PubMed ID: 9210670
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.
    Cartledge JD, Midgley J, Gazzard BG.
    AIDS; 1997 Dec; 11(15):1839-44. PubMed ID: 9412702
    [Abstract] [Full Text] [Related]

  • 15. [Investigation of the expression levels of efflux pumps in fluconazole-resistant Candida albicans isolates].
    Gulat S, Doluca Dereli M.
    Mikrobiyol Bul; 2014 Apr; 48(2):325-34. PubMed ID: 24819270
    [Abstract] [Full Text] [Related]

  • 16. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.
    Sanglard D, Ischer F, Monod M, Bille J.
    Microbiology (Reading); 1997 Feb; 143 ( Pt 2)():405-416. PubMed ID: 9043118
    [Abstract] [Full Text] [Related]

  • 17. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.
    Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M.
    J Clin Microbiol; 1994 Sep; 32(9):2092-8. PubMed ID: 7814530
    [Abstract] [Full Text] [Related]

  • 18. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis.
    Barchiesi F, Arzeni D, Del Prete MS, Sinicco A, Falconi Di Francesco L, Pasticci MB, Lamura L, Nuzzo MM, Burzacchini F, Coppola S, Chiodo F, Scalise G.
    J Antimicrob Chemother; 1998 May; 41(5):541-8. PubMed ID: 9630407
    [Abstract] [Full Text] [Related]

  • 19. The genetic basis of fluconazole resistance development in Candida albicans.
    Morschhäuser J.
    Biochim Biophys Acta; 2002 Jul 18; 1587(2-3):240-8. PubMed ID: 12084466
    [Abstract] [Full Text] [Related]

  • 20. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains.
    Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhäuser J.
    Antimicrob Agents Chemother; 1998 Dec 18; 42(12):3065-72. PubMed ID: 9835492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.